;PMID: 10189891
;source_file_539.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..38] = [t:0..38]
;1)sentence:[e:43..110] = [t:43..110]
;2)section:[e:114..173] = [t:114..173]
;3)section:[e:177..243] = [t:177..243]
;4)sentence:[e:247..621] = [t:247..621]
;5)sentence:[e:622..701] = [t:622..701]
;6)sentence:[e:702..863] = [t:702..863]
;7)sentence:[e:864..1062] = [t:864..1062]
;8)sentence:[e:1063..1221] = [t:1063..1221]
;9)sentence:[e:1222..1448] = [t:1222..1448]
;10)section:[e:1452..1497] = [t:1452..1497]

;section 0 Span:0..38
;Jpn J Cancer Res  1999 Feb;90(2):205-9
(SEC
  (FRAG (NNP:[0..3] Jpn) (NNP:[4..5] J) (NNP:[6..12] Cancer) (NNP:[13..16] Res)
        (CD:[18..22] 1999) (CD:[23..28] Feb;9) (CD:[28..29] 0)
        (-LRB-:[29..30] -LRB-) (CD:[30..31] 2) (-RRB-:[31..32] -RRB-)
        (VBP:[32..33] :) (CD:[33..35] 20) (CD:[35..38] 5-9)))

;sentence 1 Span:43..110
;Frequent beta-catenin abnormalities in bone and soft-tissue tumors.
;[52..64]:gene-rna:"beta-catenin"
;[65..78]:variation-event:"abnormalities"
;[82..86]:malignancy-type:"bone"
;[82..86]:malignancy:"bone"
;[91..109]:malignancy:"soft-tissue tumors"
(SENT
  (NP-HLN
    (NP (JJ:[43..51] Frequent) (NN:[52..64] beta-catenin)
        (NNS:[65..78] abnormalities))
    (PP-LOC (IN:[79..81] in)
      (NP
        (NP (NN:[82..86] bone)
          (NML-1 (-NONE-:[86..86] *P*)))
        (CC:[87..90] and)
        (NP (JJ:[91..102] soft-tissue)
          (NML-1 (NNS:[103..109] tumors)))))
    (.:[109..110] .)))

;section 2 Span:114..173
;Iwao K, Miyoshi Y, Nawa G, Yoshikawa H, Ochi T, Nakamura Y.
(SEC
  (FRAG (NNP:[114..118] Iwao) (NNP:[119..121] K,) (NNP:[122..129] Miyoshi)
        (NNP:[130..131] Y) (,:[131..132] ,) (NNP:[133..137] Nawa)
        (NNP:[138..140] G,) (NNP:[141..150] Yoshikawa) (NNP:[151..153] H,)
        (NNP:[154..158] Ochi) (NNP:[159..160] T) (,:[160..161] ,)
        (NNP:[162..170] Nakamura) (NNP:[171..172] Y) (.:[172..173] .)))

;section 3 Span:177..243
;Department of Medical Genetics, Biomedical Research Center, Osaka.
(SEC
  (FRAG (NNP:[177..187] Department) (IN:[188..190] of) (NNP:[191..198] Medical)
        (NNP:[199..207] Genetics) (,:[207..208] ,) (NNP:[209..219] Biomedical)
        (NNP:[220..228] Research) (NNP:[229..235] Center) (IN:[235..236] ,)
        (NNP:[237..242] Osaka) (.:[242..243] .)))

;sentence 4 Span:247..621
;We have screened mutations of the beta-catenin gene by using the polymerase 
;chain reaction-single strand conformation polymorphism (PCR-SSCP) method in
;62  malignant bone and soft-tissue tumors, including malignant fibrous
;histiocytomas  (MFHs), osteosarcomas, synovial sarcomas, liposarcomas,
;malignant schwannomas,  and other types of tumors, as well as 11 benign
;tumors.
;[281..293]:gene-rna:"beta-catenin"
;[312..322]:gene-protein:"polymerase"
;[404..418]:malignancy-type:"malignant bone"
;[404..418]:malignancy:"malignant bone"
;[423..441]:malignancy:"soft-tissue tumors"
;[453..484]:malignancy:"malignant fibrous histiocytomas"
;[487..491]:malignancy:"MFHs"
;[494..507]:malignancy:"osteosarcomas"
;[509..526]:malignancy:"synovial sarcomas"
;[528..540]:malignancy:"liposarcomas"
;[542..563]:malignancy:"malignant schwannomas"
;[607..620]:malignancy:"benign tumors"
(SENT
  (S
    (NP-SBJ (PRP:[247..249] We))
    (VP (VBP:[250..254] have)
      (VP (VBN:[255..263] screened)
        (NP
          (NP (NNS:[264..273] mutations))
          (PP (IN:[274..276] of)
            (NP (DT:[277..280] the) (NN:[281..293] beta-catenin)
                (NN:[294..298] gene))))
        (PP-MNR (IN:[299..301] by)
          (S-NOM
            (NP-SBJ (-NONE-:[301..301] *))
            (VP (VBG:[302..307] using)
              (NP (DT:[308..311] the)
                (NML
                  (NML
                    (NML (NN:[312..322] polymerase) (NN:[324..329] chain)
                         (NN:[330..338] reaction))
                    (HYPH:[338..339] -)
                    (NML (JJ:[339..345] single) (NN:[346..352] strand)
                         (NN:[353..365] conformation)
                         (NN:[366..378] polymorphism)))
                  (-LRB-:[379..380] -LRB-)
                  (NML (NN:[380..383] PCR) (HYPH:[383..384] -)
                       (NN:[384..388] SSCP))
                  (-RRB-:[388..389] -RRB-))
                (NN:[390..396] method)))))
        (PP-LOC (IN:[397..399] in)
          (NP
            (NP
              (NP (CD:[400..402] 62)
                (NML
                  (NML
                    
                    (ADJP-2 (JJ:[404..413] malignant))
                    (NN:[414..418] bone)
                    (NML-1 (-NONE-:[418..418] *P*)))
                  (CC:[419..422] and)
                  (NML
                    (ADJP-2 (-NONE-:[422..422] *P*))
                     (JJ:[423..434] soft-tissue)
                    (NML-1 (NNS:[435..441] tumors)))))
              (,:[441..442] ,)
              (PP (VBG:[443..452] including)
                (NP
                  (NP
                    (NP (JJ:[453..462] malignant) (JJ:[463..470] fibrous)
                        (NNS:[471..484] histiocytomas))
                    (NP (-LRB-:[486..487] -LRB-) (NNS:[487..491] MFHs)
                        (-RRB-:[491..492] -RRB-)))
                  (,:[492..493] ,)
                  (NP (NNS:[494..507] osteosarcomas))
                  (,:[507..508] ,)
                  (NP (JJ:[509..517] synovial) (NNS:[518..526] sarcomas))
                  (,:[526..527] ,)
                  (NP (NNS:[528..540] liposarcomas))
                  (,:[540..541] ,)
                  (NP (JJ:[542..551] malignant) (NNS:[552..563] schwannomas))
                  (,:[563..564] ,) (CC:[566..569] and)
                  (NP
                    (NP (JJ:[570..575] other) (NNS:[576..581] types))
                    (PP (IN:[582..584] of)
                      (NP (NNS:[585..591] tumors)))))))
            (,:[591..592] ,)
            (CONJP (RB:[593..595] as) (RB:[596..600] well) (IN:[601..603] as))
            (NP (CD:[604..606] 11)
               (JJ:[607..613] benign) (NNS:[614..620] tumors))))))
    (.:[620..621] .)))

;sentence 5 Span:622..701
;beta-Catenin-activating  missense mutations were found in two malignant
;tumors.
;[622..634]:gene-rna:"beta-Catenin"
;[647..665]:variation-type:"missense mutations"
;[684..700]:malignancy:"malignant tumors"
(SENT
  (S
    (NP-SBJ-1
      (ADJP (NN:[622..634] beta-Catenin) (HYPH:[634..635] -)
            (VBG:[635..645] activating))
       (JJ:[647..655] missense) (NNS:[656..665] mutations))
    (VP (VBD:[666..670] were)
      (VP (VBN:[671..676] found)
        (NP-1 (-NONE-:[676..676] *))
        (PP-LOC (IN:[677..679] in)
          (NP (CD:[680..683] two)
             (JJ:[684..693] malignant) (NNS:[694..700] tumors)))))
    (.:[700..701] .)))

;sentence 6 Span:702..863
;One found in MFH occurred  at codon 45 and caused an amino acid substitution
;from serine (one of the GSK3  beta-targeted phosphorylation sites) to
;phenylalanine.
;[715..718]:malignancy:"MFH"
;[732..740]:variation-location:"codon 45"
;[755..778]:variation-type:"amino acid substitution"
;[784..790]:variation-state-original:"serine"
;[803..813]:gene-protein:"GSK3  beta"
;[849..862]:variation-state-altered:"phenylalanine"
(SENT
  (S
    (NP-SBJ
      (NP (CD:[702..705] One))
      (VP (VBN:[706..711] found)
        (NP (-NONE-:[711..711] *))
        (PP-LOC (IN:[712..714] in)
          (NP (NN:[715..718] MFH)))))
    (VP
      (VP (VBD:[719..727] occurred)
        (PP-LOC (IN:[729..731] at)
          (NP (NN:[732..737] codon) (CD:[738..740] 45))))
      (CC:[741..744] and)
      (VP (VBD:[745..751] caused)
        (NP
          (NP (DT:[752..754] an)
            
            (NML (JJ:[755..760] amino) (NN:[761..765] acid))
            (NN:[766..778] substitution))
          (PP (IN:[779..783] from)
            (NP (NN:[784..790] serine)
              (PRN (-LRB-:[791..792] -LRB-)
                (NP
                  (NP (CD:[792..795] one))
                  (PP (IN:[796..798] of)
                    (NP (DT:[799..802] the)
                      (ADJP
                        (NML (NN:[803..807] GSK3) (SYM:[809..813] beta))
                        (HYPH:[813..814] -) (VBN:[814..822] targeted))
                      (NN:[823..838] phosphorylation) (NNS:[839..844] sites))))
                (-RRB-:[844..845] -RRB-))))
          (PP (TO:[846..848] to)
            (NP (NN:[849..862] phenylalanine))))))
    (.:[862..863] .)))

;sentence 7 Span:864..1062
;The other, detected in  synovial sarcoma at codon 32, resulted in an amino
;acid change from aspartic  acid (located adjacent to the phosphorylation
;target, serine, encoded by codon  33) to tyrosine.
;[888..904]:malignancy:"synovial sarcoma"
;[908..916]:variation-location:"codon 32"
;[933..950]:variation-type:"amino acid change"
;[956..970]:variation-state-original:"aspartic  acid"
;[1039..1048]:variation-location:"codon  33"
;[1053..1061]:variation-state-altered:"tyrosine"
(SENT
  (S
    (NP-SBJ
      (NP (DT:[864..867] The) (NN:[868..873] other))
      (,:[873..874] ,)
      (VP (VBN:[875..883] detected)
        (NP (-NONE-:[883..883] *))
        (PP (IN:[884..886] in)
          (NP (JJ:[888..896] synovial) (NN:[897..904] sarcoma)))
        (PP-LOC (IN:[905..907] at)
          (NP (NN:[908..913] codon) (CD:[914..916] 32)))))
    (,:[916..917] ,)
    (VP (VBD:[918..926] resulted)
      (PP-CLR (IN:[927..929] in)
        (NP
          (NP (DT:[930..932] an)
            
            (NML (JJ:[933..938] amino) (NN:[939..943] acid))
            (NN:[944..950] change))
          (PP (IN:[951..955] from)
            (NP
               (JJ:[956..964] aspartic) (NN:[966..970] acid)
              (PRN (-LRB-:[971..972] -LRB-)
                (VP (VBN:[972..979] located)
                  (S
                    (NP-SBJ (-NONE-:[979..979] *))
                    (ADJP-PRD (JJ:[980..988] adjacent)
                      (PP (TO:[989..991] to)
                        (NP
                          (NP
                            (NP (DT:[992..995] the)
                                (NN:[996..1011] phosphorylation)
                                (NN:[1012..1018] target))
                            (,:[1018..1019] ,)
                            (NP (NN:[1020..1026] serine)))
                          (,:[1026..1027] ,)
                          (VP (VBN:[1028..1035] encoded)
                            (NP (-NONE-:[1035..1035] *))
                            (PP (IN:[1036..1038] by)
                              (NP-LGS (NN:[1039..1044] codon)
                                      (CD:[1046..1048] 33)))))))))
                (-RRB-:[1048..1049] -RRB-))))
          (PP (TO:[1050..1052] to)
            (NP (NN:[1053..1061] tyrosine))))))
    (.:[1061..1062] .)))

;sentence 8 Span:1063..1221
;Furthermore, we found accumulation of beta-catenin by  western-blotting
;analysis in 12 of 19 malignant tumors in which we found no  mutation
;involving exon 3.
;[1101..1113]:gene-protein:"beta-catenin"
;[1156..1172]:malignancy:"malignant tumors"
;[1191..1203]:variation-event:"no  mutation"
;[1214..1220]:variation-location:"exon 3"
(SENT
  (S
    (ADVP (RB:[1063..1074] Furthermore))
    (,:[1074..1075] ,)
    (NP-SBJ (PRP:[1076..1078] we))
    (VP (VBD:[1079..1084] found)
      (NP
        (NP (NN:[1085..1097] accumulation))
        (PP (IN:[1098..1100] of)
          (NP (NN:[1101..1113] beta-catenin))))
      (PP-MNR (IN:[1114..1116] by)
        (NP
          (NML (JJ:[1118..1125] western) (HYPH:[1125..1126] -)
               (NN:[1126..1134] blotting))
          (NN:[1135..1143] analysis)))
      (PP-LOC (IN:[1144..1146] in)
        (NP
          (NP (CD:[1147..1149] 12))
          (PP (IN:[1150..1152] of)
            (NP
              (NP (CD:[1153..1155] 19)
                 (JJ:[1156..1165] malignant) (NNS:[1166..1172] tumors))
              (SBAR
                (WHPP-1 (IN:[1173..1175] in)
                  (WHNP (WDT:[1176..1181] which)))
                (S
                  (NP-SBJ (PRP:[1182..1184] we))
                  (VP (VBD:[1185..1190] found)
                    (NP
                      (NP (DT:[1191..1193] no) (NN:[1195..1203] mutation))
                      (VP (VBG:[1204..1213] involving)
                        (NP (NN:[1214..1218] exon) (CD:[1219..1220] 3))))
                    (PP-LOC-1 (-NONE-:[1220..1220] *T*))))))))))
    (.:[1220..1221] .)))

;sentence 9 Span:1222..1448
;Our results suggested the possible involvement of  beta-catenin activation,
;by beta-catenin gene mutation or alteration of other  factor(s), in the
;formation and/or progression of various types of bone and  soft-tissue
;tumors.
;[1273..1285]:gene-rna:"beta-catenin"
;[1301..1313]:gene-rna:"beta-catenin"
;[1319..1327]:variation-event:"mutation"
;[1419..1423]:malignancy-type:"bone"
;[1419..1423]:malignancy:"bone"
;[1429..1447]:malignancy:"soft-tissue tumors"
(SENT
  (S
    (NP-SBJ (PRP$:[1222..1225] Our) (NNS:[1226..1233] results))
    (VP (VBD:[1234..1243] suggested)
      (NP
        (NP (DT:[1244..1247] the) (JJ:[1248..1256] possible)
            (NN:[1257..1268] involvement))
        (PP (IN:[1269..1271] of)
          (NP (NN:[1273..1285] beta-catenin) (NN:[1286..1296] activation)))
        (,:[1296..1297] ,)
        (PP (IN:[1298..1300] by)
          (NP
            (NP (NN:[1301..1313] beta-catenin) (NN:[1314..1318] gene)
                (NN:[1319..1327] mutation))
            (CC:[1328..1330] or)
            (NP
              (NP (NN:[1331..1341] alteration))
              (PP (IN:[1342..1344] of)
                (NP (JJ:[1345..1350] other) (NNS:[1352..1361] factor-LRB-s-RRB-))))))
        (,:[1361..1362] ,)
        (PP (IN:[1363..1365] in)
          (NP
            (NP (DT:[1366..1369] the) (NN:[1370..1379] formation)
                (CC:[1380..1386] and/or) (NN:[1387..1398] progression))
            (PP (IN:[1399..1401] of)
              (NP
                (NP (JJ:[1402..1409] various) (NNS:[1410..1415] types))
                (PP (IN:[1416..1418] of)
                  (NP
                    (NP (NN:[1419..1423] bone)
                      (NML-1 (-NONE-:[1423..1423] *P*)))
                    (CC:[1424..1427] and)
                    (NP (JJ:[1429..1440] soft-tissue)
                      (NML-1 (NNS:[1441..1447] tumors)))))))))))
    (.:[1447..1448] .)))

;section 10 Span:1452..1497
;PMID: 10189891 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1452..1456] PMID) (::[1456..1457] :) (CD:[1458..1466] 10189891)
        (NN:[1467..1468] -LSB-) (NNP:[1468..1474] PubMed) (::[1475..1476] -)
        (NN:[1477..1484] indexed) (IN:[1485..1488] for)
        (NNP:[1489..1497] MEDLINE-RSB-)))
